Results from the iAdhere trial conducted through the TB Trials Consortium have been published in the Annals of Internal Medicine. This randomized trial aimed to compare treatment completion and safety of once-weekly isoniazid and rifapentine by self-administration versus direct observation. Enrollment sites were located in the US, Spain, Hong Kong, and South Africa; Vanderbilt and the Metro Nashville Health Department participated in enrollment.
The results of this study support using self-administered, once-weekly isoniazid and rifapentine to treat latent TB infection in the United States, and such treatment could be considered in similar settings when DOT is not feasible.
Editorial: Tailoring Treatment of Latent Tuberculosis to the Needs of Patients and Families
Study and Editorial Summary: Self-administered treatment appears effective for latent tuberculosis